Clinical Trials Directory

A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

The purpose of this study is to determine the effect of the study drug, MPDL3280A (a monoclonal antibody) on programmed cell death-1 ligand 1 (PD-L1)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). The study also aims to learn more about the safety and tolerability of the study drug.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : Atezolizumab

Phase: Phase 2

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Stage IIIB (not eligible for definitive chemoradiotherapy), Stage IV, or recurrent non-small cell lung cancer (NSCLC) - PDL1-positive status as determined by an IHC assay performed by a central laboratory - ECOG Performance Status of 0 or 1 - Life expectancy >= 12 weeks - Measurable disease, as defined by RECIST v1.1 - Adequate hematologic and end organ function

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Lisa Zhou
650-736-4112
Not Recruiting

Footer Links: